IGF-1定量检测及其在前列腺癌诊断中的价值

Quantitative Analysis of IGF-1 and Its Application in the Diagnosis of Prostate Cancer

目的 定量测定血清中胰岛素样生长因子 - 1(IGF- 1)的含量并探讨其在前列腺癌诊断中的作用。方法 建立双位点免疫放射测定法 (IRMA)对 81例前列腺癌、5 5例前列腺增生 (BPH)、32例泌尿系统肿瘤患者及 84例正常男性对照血清 IGF- 1进行检测 ,并对 38例 BPH患者 IGF- 1和前列腺特异抗原 (PSA)含量进行为期1年定期随访检测。结果 IRMA检测 IGF- 1在 8～ 10 0 0 mg/ L 内线性良好 (r=0 .98) ,最低检测限为 2 m g/ L,平均回收率 94.5 % ;IGF- 1高值 (382 .4mg/ L)、低值 (32 .5 m g/ L) ;批内重复性测定的 CV分别为 7.2 %和 4.2 % ;胰岛素、生长激素及 IGF- 2不干扰该方法对 IGF- 1的测定 (<3mg/ L) ;前列腺癌患者的 IGF- 1含量较正常对照、BPH及泌尿系统肿瘤患者显著增高 (P<0 .0 5 ) ,比数比和其 95 %的可性限分别为 2 .86和 1.38～ 5 .34,特异性和敏感性分别为 0 .6 8和 0 .5 8,而且 IGF- 1在前列腺癌的发生过程中有呈进行性增高趋势。结论 IGF-

Objective To quantify the level of insulin like growth factor (IGF 1) in serum and investigate its role in the diagnosis of prostate cancer. Methods IGF 1 immunoradiometric assay (IRMA) was set up and used to determine serum IGF 1 level in patients with prostate cancer ( n = 81), benign prostate hyperplasia (BPH, n =55) , uroepithelial tumor ( n =32) and healthy male controls ( n =84). Furthermore, the levels of IGF 1 and prostate specific antigen (PSA) in 38 patients with BPH were determined every three months for one year. Results Linearity was well demonstrated for IGF 1 in the range of 8～1000 ng ( r =0.98), the lowest limit for detecting IGF 1 being 2 mg/L and the mean recovery for detecting IGF 1 being 94.5%. The within replicate coefficient of variance (CV) of IGF 1 detection was 7.2% for a higher level(382.4 mg/L) and 4.2% for a low level (32.5 mg/L) of IGF 1.Insulin, growth factor or IGF 2 did not interfere with the detection of IGF 1(<3ml/L).There was high level of IGF 1 in patients with prostate cancer than in healthy controls, patients with BPH and uroepithelial tumor ( P <0.05); the odds ratio and its 95% confidence intervals were 2.86 and 1.38 5.34, respectively; the specificity and sensitivity of IGF 1 determination were 0.68 and 0.58, respectively; furthermore, the level of IGF 1 was increased during the development of prostate cancer. Conclusions these findings demonstrate that IGF 1 may serve prospectively as an important tumor marker in the diagnosis and prediction of prostate cancer.